Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SGEN

SGEN - Seattle Genetics Inc Stock Price, Fair Value and News

$3711.48 
Market Closed

SGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SGEN Price Action

SGEN RSI Chart

SGEN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SGEN Valuation

SGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SGEN Fundamentals

SGEN Revenue

SGEN Earnings

SGEN Profitability

SGEN Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.1B2.2B2.3B0
20221.7B1.8B1.9B2.0B
20212.3B2.4B1.7B1.6B
2020956.0M1.0B1.9B2.2B
2019709.3M757.6M801.4M916.7M
2018513.7M575.7M609.8M654.7M
2017416.1M428.9M457.9M482.3M
2016365.8M384.1M406.3M418.1M
2015300.6M309.4M317.7M336.8M
2014280.2M275.0M279.8M286.8M
2013219.9M244.6M265.8M269.3M
2012130.9M166.6M195.8M210.8M
201173.2M49.4M54.0M94.8M
201065.8M79.7M93.6M107.5M
200900052.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Seattle Genetics Inc

SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
 CEO
 WEBSITEseagen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES3256